MAP3K3 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL371758	0.87	2/20
SCHEMBL371897	0.82	2/20
SCHEMBL372005	0.73	2/20
SCHEMBL372006	0.73	2/20
SCHEMBL371938	0.73	2/20
SCHEMBL372270	0.73	2/20
SCHEMBL371886	0.60	2/20
SCHEMBL371898	0.57	2/20
SCHEMBL372007	0.56	2/20
SCHEMBL372225	0.56	2/20
SCHEMBL371939	0.55	2/20
SCHEMBL372271	0.55	2/20
Motesanib (SCHEMBL187470)	1.00	1/20
Amg-900 (SCHEMBL503564)	1.00	1/20
Motesanib (SCHEMBL445079)	0.98	1/20
Motesanib (SCHEMBL446673)	0.95	1/20
SCHEMBL581178	0.84	1/20
SCHEMBL580354	0.84	1/20
SCHEMBL581542	0.82	1/20
SCHEMBL581159	0.81	1/20

Clinical trials — most relevant to MAP3K3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma	PHASE4	UNKNOWN
Molecular Mechanisms of Type 2 Diabetes Mellitus	PHASE4	COMPLETED
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome	PHASE3	COMPLETED
HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma	PHASE1/PHASE2	COMPLETED
Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations	PHASE2	ACTIVE_NOT_RECRUITING
Dabrafenib + Trametinib + PDR001 In Colorectal Cancer	PHASE2	UNKNOWN
A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma	PHASE1/PHASE2	COMPLETED
Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer	PHASE2	COMPLETED
A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations	PHASE2	RECRUITING
To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib.	PHASE2	UNKNOWN
Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer	PHASE2	COMPLETED
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer	PHASE2	COMPLETED
MEK162 for Patients With RAS/RAF/MEK Activated Tumors	PHASE2	COMPLETED
Selective Treatment According to Molecular Subtype of Prostate Cancer	PHASE2	UNKNOWN
Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma	PHASE2	COMPLETED
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma	PHASE1/PHASE2	SUSPENDED
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212	PHASE1	COMPLETED
Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer	PHASE1	COMPLETED
Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101	PHASE1	WITHDRAWN
Nilotinib in Huntington's Disease	PHASE1	UNKNOWN
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212	EARLY_PHASE1	COMPLETED
Evaluation of Human Melanocytes After the Use of PRP Versus Fractional CO2 Laser in Vitiligo	nan	UNKNOWN
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies	nan	RECRUITING
Molecular Analysis of Thoracic Malignancies	nan	ENROLLING_BY_INVITATION
BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients	nan	COMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment	nan	ACTIVE_NOT_RECRUITING
Clinical Genetics Branch Eligibility Screening Survey	nan	NOT_YET_RECRUITING
Histiocytic Disorder Follow-up Study	nan	RECRUITING
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a MAP3K3 binder may also engage these)

Protein	Name	Similarity
Q61084	—	1.000	Q61084 →
Q61083	—	1.000	Q61083 →
MAP3K2	Mitogen-activated protein kinase kinase kinase 2	1.000	landscape →
O35346	—	0.992	O35346 →
PTK2	Focal adhesion kinase 1	0.992	landscape →
Q5R5M7	—	0.989	Q5R5M7 →
Q62073	—	0.988	Q62073 →
Q8C0D4	—	0.988	Q8C0D4 →
P34152	—	0.988	P34152 →
A2VDU3	—	0.988	A2VDU3 →
Q91738	—	0.988	Q91738 →
P0C8E4	—	0.987	P0C8E4 →
P11345	—	0.987	P11345 →
E9PUQ8	—	0.987	E9PUQ8 →
Q69Z98	—	0.987	Q69Z98 →
Q5U2Z7	—	0.986	Q5U2Z7 →
Q00944	—	0.986	Q00944 →
P11346	—	0.986	P11346 →
O43295	—	0.986	O43295 →
PTPN14	Tyrosine-protein phosphatase non-receptor type 14	0.986	landscape →
P34908	—	0.986	P34908 →
Q6PJI9	—	0.986	Q6PJI9 →
Q5RJI5	—	0.986	Q5RJI5 →
Q03141	—	0.986	Q03141 →
KSR2	Kinase suppressor of Ras 2	0.986	landscape →
Q9CQ73	—	0.985	Q9CQ73 →
Q812E4	—	0.985	Q812E4 →
BRSK2	Serine/threonine-protein kinase BRSK2	0.985	landscape →
RAF1	RAF proto-oncogene serine/threonine-protein kinase	0.985	landscape →
PTK2B	Protein-tyrosine kinase 2-beta	0.985	landscape →